Related Experiment Video
Updated: Oct 6, 2025
Optical Monitoring of Living Nerve Terminal Labeling in Hair Follicle Lanceolate Endings of the Ex Vivo Mouse Ear Skin
Published on: April 5, 2016
Scanning electron microscopy of panitumumab-induced eyelash and hair alterations - Pili canaliculi
Debora Sarzi Sartori1, Antônia Larangeira de Almeida2, Gabriel Santana Pereira de Oliveira2
1Post-graduation Program in Health, Universidade Católica de Pelotas, Pelotas, RS, Brazil; Department of Dermatology, Universidade Federal de Pelotas, Pelotas, RS, Brazil.
Abstract:
Panitumumab is a monoclonal antibody against the epidermal growth factor receptor used in metastatic colorectal cancer; in addition to tumor cells, it acts on epidermal keratinocytes and on the outer root sheath and presents skin toxicity in up to 90% of cases. A scanning electron microscope was used to examine the eyelashes and hairs of a 65-year-old patient with eyelash trichomegaly, curly hair, and paronychia undergoing treatment with panitumumab. Grooving in the hair shafts were identified, which were more evident in the eyelashes. Similar to oral epidermal growth factor inhibitors (erlotinib and gefitinib), panitumumab can cause acquired pili canaliculi.
Insights
Panitumumab, a cancer drug, can cause hair and eyelash changes. This study identified grooving in hair shafts, similar to a condition called acquired pili canaliculi, in a patient treated with panitumumab.
Area of Science:
- Oncology
- Dermatology
- Pharmacology
Background:
- Panitumumab is a monoclonal antibody targeting the epidermal growth factor receptor (EGFR).
- It is utilized in treating metastatic colorectal cancer.
- Panitumumab is known to cause skin toxicity in up to 90% of patients.
Observation:
- A 65-year-old patient undergoing panitumumab treatment presented with eyelash trichomegaly, curly hair, and paronychia.
- Scanning electron microscopy was employed to examine the patient's eyelashes and hair shafts.
- The examination revealed distinct grooving within the hair shafts, particularly noticeable on the eyelashes.
Findings:
- The observed hair shaft abnormalities are consistent with acquired pili canaliculi.
- This condition involves characteristic grooving or channeling along the hair shaft.
- These findings are similar to those reported with other EGFR inhibitors like erlotinib and gefitinib.
Implications:
- Panitumumab, like other EGFR inhibitors, can induce specific hair shaft abnormalities.
- Understanding these side effects is crucial for managing patient care during cancer treatment.
- Further research may elucidate the precise mechanisms behind EGFR inhibitor-induced hair changes.
